Targeted nanoparticles to deliver a multimodal peptide to head and neck tumors

靶向纳米颗粒将多模式肽递送至头颈肿瘤

• 批准号: 8580801
• 负责人: Niranjan B Pandey
• 金额: $ 25.8万
• 依托单位: ASCLEPIX THERAPEUTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-07-01 至 2016-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8580801
• 关键词: Angiogenic Factor; Benign; Biodistribution; Biological Assay; Biological Products; Biotechnology; Blood; Blood Vessels; Cancer Etiology; Cancer Model; Cause of Death; Cell-Cell Adhesion; Cells; Clinical; Disadvantaged; Drug Formulations; Effectiveness; Encapsulated; Growth; Half-Life; Head and Neck Cancer; Head and Neck Neoplasms; Head and neck structure; Human Papillomavirus; Image; In Vitro; Lead; Ligands; Malignant Neoplasms; Malignant Squamous Cell Neoplasm; Modeling; Pathway interactions; Peptides; Phase; Property; Resistance; Resistance development; Safety; Signal Transduction; Site; System; Therapeutic; Therapeutic Agents; Tissues; Tumor Angiogenesis; United States; Xenograft procedure; angiogenesis; bevacizumab; biophysical properties; cancer therapy; cell motility; controlled release; design; in vivo; mimetics; mouse model; nanoparticle; neoplastic cell; novel; novel therapeutics; particle; public health relevance; targeted delivery; therapy resistant; tumor; tumorigenic

DESCRIPTION (provided by applicant): There are very limited options currently available for the treatment of HPV(-) head and neck squamous cell cancer (HNSCC), the sixth leading cause of cancer in the United States and worldwide. HNSCC, like most forms of cancer, is dependent on angiogenesis, the growth of blood vessels. We have developed a mimetic multimodal peptide that inhibits growth of tumor angiogenesis and directly inhibits tumor cell adhesion and migration. Tumors treated with this multimodal peptide are less likely to develop resistance to therapy because it inhibits signals from a broad range of tumor-secreted factors. In this project we will create a novel targeted nanoparticle delivery vehicle for this peptide. The nanoparticle-encapsulated peptide will be administered systemically and will accumulate in the tumor and its vasculature in order to enhance both efficacy and safety. Successful completion of the project will result in the creation of a powerful, new therapeutic for the treatment of HNSCC and also help a startup biotechnology company reach a critical milestone.

描述（由申请人提供）：目前可用于治疗HPV（-）头颈部鳞状细胞癌（HNSCC）的选择非常有限，HNSCC是美国和全球第六大癌症原因。HNSCC与大多数癌症一样，依赖于血管生成，即血管的生长。我们已经开发了一种模拟多模式肽，其抑制肿瘤血管生成的生长并直接抑制肿瘤细胞粘附和迁移。用这种多模式肽治疗的肿瘤不太可能对治疗产生耐药性，因为它抑制了来自广泛的肿瘤分泌因子的信号。在这个项目中，我们将为这种肽创建一种新的靶向纳米颗粒递送载体。纳米颗粒包封的肽将被全身施用，并将在肿瘤及其脉管系统中积累，以增强功效和安全性。该项目的成功完成将为HNSCC的治疗创造一种强大的新疗法，并帮助一家初创生物技术公司达到一个关键的里程碑。